Raptor Pharmaceutical Corp. (NASDAQ:RPTP) rose 5.1% during trading on Thursday . The company traded as high as $6.23 and last traded at $6.02, with a volume of 323,003 shares traded. The stock had previously closed at $5.73.

RPTP has been the topic of a number of analyst reports. Cowen and Company reaffirmed a “buy” rating and set a $8.00 price objective on shares of Raptor Pharmaceutical Corp. in a research note on Sunday, April 17th. FBR & Co reaffirmed a “hold” rating on shares of Raptor Pharmaceutical Corp. in a research note on Sunday, June 12th. Oppenheimer Holdings Inc. reaffirmed a “market perform” rating on shares of Raptor Pharmaceutical Corp. in a research note on Monday, April 11th. Wedbush reaffirmed a “neutral” rating and set a $4.00 price objective on shares of Raptor Pharmaceutical Corp. in a research note on Friday, May 6th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $11.00 price objective on shares of Raptor Pharmaceutical Corp. in a research note on Tuesday, April 12th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $11.00.

The company’s market cap is $511.84 million. The stock’s 50 day moving average price is $5.56 and its 200-day moving average price is $4.70.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last issued its quarterly earnings data on Thursday, May 5th. The company reported ($0.17) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.17). During the same quarter in the prior year, the firm posted ($0.24) EPS. The firm earned $27.47 million during the quarter, compared to analysts’ expectations of $27.17 million. Raptor Pharmaceutical Corp.’s quarterly revenue was up 34.3% compared to the same quarter last year. Equities analysts expect that Raptor Pharmaceutical Corp. will post ($0.99) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Raptor Pharmaceutical Corp. stock. Cornerstone Capital Management Holdings LLC. boosted its position in shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) by 319.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 251,803 shares of the company’s stock after buying an additional 191,703 shares during the period. Cornerstone Capital Management Holdings LLC. owned about 0.30% of Raptor Pharmaceutical Corp. worth $1,310,000 at the end of the most recent reporting period.

Raptor Pharmaceutical Corp. is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Company’s product, PROCYSBI delayed-release capsules received marketing approval from the FDA for the management of nephropathic cystinosis in adults and children six years and older.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.